Gault Cheryl Insider Trades

Insider Trading History

Track insider trading activity for Gault Cheryl. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.02M 162,753 shares
Last Trade
Mar 30, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$282k 10,000 shares
$28.19
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.29M 169,914 shares
Last Trade
Mar 05, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$58.3k 2,014 shares
$28.93
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $4.88M 132,000 shares
Last Trade
Feb 02, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$3.66M 132,000 shares
$27.75
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $3.9M 105,407 shares
Last Trade
Nov 26, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$147k 5,000 shares
$29.43
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.55M 176,928 shares
Last Trade
Nov 26, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$147k 5,000 shares
$29.43
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.36M 171,928 shares
Last Trade
Nov 26, 2025 Sale (Open Market)Shares sold on the open market or in a private sale.
$151k 5,000 shares
$30.10
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.55M 176,928 shares
Last Trade
Sep 08, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$157k 5,000 shares
$31.47
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.36M 171,928 shares
Last Trade
Sep 08, 2025 Sale (Open Market)Shares sold on the open market or in a private sale.
$157k 5,000 shares
$31.47
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $4.09M 110,407 shares
Last Trade
Sep 08, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$157k 5,000 shares
$31.47
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $6.36M 171,928 shares
Last Trade
Mar 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$100k 13,987 shares
$7.15
$37.00
Rapport Therapeutics
Rapport Therapeutics RAPP
Chief Operating Officer
Holding Value $4.77M 129,000 shares
Last Trade
Feb 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.14M 129,000 shares
$16.60
$37.00
Cyclerion Therapeutics
Cyclerion Therapeutics CYCN
Chief Operating Officer
Holding Value $405k 135,000 shares
Last Trade
Jan 20, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$65.3M 135,000 shares
$484.00
$3.00
Cyclerion Therapeutics
Cyclerion Therapeutics CYCN
Chief Operating Officer
Holding Value $300k 100,000 shares
Last Trade
Dec 09, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$77.2M 100,000 shares
$772.00
$3.00
Cyclerion Therapeutics
Cyclerion Therapeutics CYCN
Chief Operating Officer
Holding Value $25.5k 8,500 shares
Last Trade
Jan 01, 2021 Sale
$327M 267,342 shares
$1,224.00
$3.00

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up